BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3952519)

  • 1. The antitumor effect of prednimustine in vitro and in vivo.
    Hartley-Asp B
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):3-7. PubMed ID: 3952519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer.
    Løber J; Mouridsen HT; Christiansen IE; Dombernowsky P; Mattsson W; Rørth M
    Cancer; 1983 Nov; 52(9):1570-6. PubMed ID: 6352005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line.
    Hartley-Asp B; Gunnarsson PO; Liljekvist J
    Cancer Chemother Pharmacol; 1986; 16(2):85-90. PubMed ID: 3948307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative carcinogenic activity of prednimustine, chlorambucil, prednisolone and chlorambucil plus prednisolone in Sprague-Dawley rats.
    Berger MR; Habs M; Schmähl D
    Arch Geschwulstforsch; 1985; 55(6):429-42. PubMed ID: 4083998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term toxicology effects of prednimustine in comparison with chlorambucil, prednisolone, and chlorambucil plus prednisolone in Sprague-Dawley rats.
    Berger MR; Habs M; Schmähl D
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):8-13. PubMed ID: 3952521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration.
    Loos U; Musch E; Malek M; Riedel E
    Oncology; 1991; 48(4):334-42. PubMed ID: 1891177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of prednimustine and chlorambucil in the rat.
    Newell DR; Shepherd CR; Harrap KR
    Cancer Chemother Pharmacol; 1981; 6(1):85-91. PubMed ID: 7273268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients.
    Bastholt L; Johansson CJ; Pfeiffer P; Svensson L; Johansson SA; Gunnarsson PO; Mouridsen H
    Cancer Chemother Pharmacol; 1991; 28(3):205-10. PubMed ID: 1855277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednimustine in advanced breast cancer: a review.
    Mouridsen HT
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):27-31. PubMed ID: 3513318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and cell-biological investigation of prednimustine compared to its components chlorambucil and prednisolone.
    Musch E; Loos U; Alléra A; Hügl E; Pütz I; Malek M
    J Chemother; 1989 Jul; 1(4 Suppl):1127-9. PubMed ID: 16312803
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone.
    Ideström K; Kimby E; Björkholm M; Mellstedt H; Engstedt L; Gahrton G; Johansson B; Killander D; Robérts KH; Stalfelt AM; Udén AM; Wadman B; Wählby S
    Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1117-23. PubMed ID: 6897633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the cytotoxic effect of prednimustine in cultured cells with high or low levels of metallothionein.
    Endresen L
    Acta Pharmacol Toxicol (Copenh); 1984 Jan; 54(1):49-57. PubMed ID: 6702467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the pharmacokinetics of chlorambucil and prednimustine in man.
    Newell DR; Calvert AH; Harrap KR; McElwain TJ
    Br J Clin Pharmacol; 1983 Feb; 15(2):253-8. PubMed ID: 6849759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednisolone plasma levels after oral administration of Prednimustine. Comparison with levels obtained after administration of an equimolar dose of prednisolone.
    Sayed A; Hove WV; Vermeulen A
    Oncology; 1981; 38(6):351-5. PubMed ID: 7301281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031).
    Ehrsson H; Wallin I; Nilsson SO; Johansson B
    Eur J Clin Pharmacol; 1983; 24(2):251-3. PubMed ID: 6840176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prednimustine: the rationale for clinical development.
    Schein PS; Cavalli F
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):1-2. PubMed ID: 3952515
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.
    Leonard RC; Smart GE; Livingstone JR; Cornbleet MA; Kerr GR; Fletcher S; Webb JN; Smyth JF
    Cancer Chemother Pharmacol; 1989; 23(2):105-10. PubMed ID: 2491962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammary tumour inhibition and subacute toxicity in rats of prednimustine and of its molecular components chlorambucil and prednisolone.
    Fredholm B; Gunnarsson K; Jensen G; Müntzing J
    Acta Pharmacol Toxicol (Copenh); 1978 Mar; 42(3):159-63. PubMed ID: 580343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: results of a national cancer care program in Sweden.
    Cavallin-Ståhl E; Möller TR
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):19-22. PubMed ID: 3952518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of prednimustine in treating non Hodgkin's lymphomas of favourable histological type.
    Klener P; Háber J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(1):103-8. PubMed ID: 2581855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.